Integrin αvβ6-targeted PET in Malignant Tumors

Launched by ZHONGNAN HOSPITAL · Apr 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique for detecting malignant tumors, which are dangerous cancers that can grow and spread in the body. The researchers are testing a special imaging agent called 68Ga-Trivehexin that targets a specific protein found mainly in cancer cells. This new approach aims to improve how doctors can see and evaluate tumors compared to the commonly used method, 18F-FDG PET imaging, which has some limitations. The goal is to find out if this new imaging probe can provide clearer and more accurate information about different types of tumors.

To participate in the trial, individuals must be between the ages of 65 and 74 and have a suspected or confirmed malignant tumor. It's important that participants are willing to sign a consent form to join the study. Women who are pregnant or planning to become pregnant within six months, as well as those with specific allergies or who have recently participated in other trials, are not eligible. If you join the trial, you can expect to undergo imaging tests to help researchers learn more about the effectiveness of this new method in detecting cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
• • Age ≥18 years, regardless of gender;
• • No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
• • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
• • Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;
• • Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.
• Exclusion Criteria:
• • Known allergy to injection or its excipients;
• • Severe liver or renal dysfunction;
• • Claustrophobia or other psychiatric disorders;
• • History of other malignant tumors;
• • Participation in another clinical trial within 30 days prior to PET/CT scan;
• • Pregnant or breastfeeding women;
• • Refusal to participate or request for withdrawing from the clinical study;
• • Other conditions deemed unsuitable for inclusion by investigator.